Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials.
about
Clinical management of infections caused by multidrug-resistant EnterobacteriaceaeAn update on the management of urinary tract infections in the era of antimicrobial resistance.Designer aminoglycosides prevent cochlear hair cell loss and hearing lossAnticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsEmpiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysisInfluence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.Plazomicin: an investigational therapy for the treatment of urinary tract infections.Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urineCombination therapy for treatment of infections with gram-negative bacteria.Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogensImpact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.Aminoglycoside drugs in clinical practice: an evidence-based approach.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic model.Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Aminoglycoside therapy in infectious diseases.Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.Sparing carbapenem usage.Restrictive antibiotic stewardship associated with reduced hospital mortality in gram-negative infection.Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.Management of aminoglycosides in the intensive care unit.Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed.Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial.
P2860
Q28246841-9A7AF306-EB8C-4C7B-9121-130B7AF1578AQ30244815-68F33CD5-5CAE-46EC-9264-288130B5286CQ30619790-88AFD01C-5A7B-4C22-B2AE-476294919C66Q33732524-678985DA-9298-41A1-BD15-413ACDB6E9D6Q33826400-91797AC0-BD24-48FD-B1FF-FCA6E69366DBQ34108527-AADA431A-4A48-4F76-B4EB-60465F545BFEQ34673393-C595787A-4EC4-43AF-A1BA-1A933A532937Q34906223-C790FF89-4D89-414B-AF21-9BB182F0AFE0Q35278325-A82A25DB-68BD-46B1-8EA0-08836753EE52Q35598359-7D923971-BACC-46B6-8C1B-B140797E563AQ36156077-06C6948E-0A30-44A1-BE4A-3F486E35C78AQ36172460-BEAA2A68-1E97-43D5-BF0F-22F260E609FBQ36854025-CB65EF03-76C6-43DF-98E5-74238B1D4992Q37247110-E69E0B73-F2CE-4A9D-88E9-889B98DC1F36Q37331044-17653F38-4923-466E-B053-71411E57F7D7Q37656243-7829740E-C419-4DD4-8198-4266073FDBB4Q37933361-99211208-FDFA-45AB-8A8F-45D5EAB87073Q38070006-0DEF5DB7-7B43-4FA3-9DD2-BA380086FFD2Q38090988-F5C540CB-E8D2-404E-9F3B-EDB1F6E929C9Q38112810-E114BBB8-486A-4BE6-B1EE-BC5BE02667C0Q38199180-89E74B6E-0B65-43F2-B0E7-8D1493B36A32Q38212031-E982A0DF-2E52-42A4-B9DA-502CDD4C8E20Q38306504-49362205-0D1C-4500-9B16-A1D69A2EACF2Q38867747-A0B3BFF5-F9BC-4FE2-8AA0-BF094C85193AQ39388468-C34F92D4-259C-4724-924D-BC369FE3F68EQ39493195-10C510D9-F86A-434D-8A87-0B8A537A2B57Q40131663-559CD780-DD97-4F45-BCF2-D716286B834DQ40265579-CD4D62D3-F5C3-4C4B-9EEB-7EAF87A107AAQ41676553-D4FE7BF3-A8FE-47F7-898F-1D83AC93C151Q41987129-B2A67BBE-8CE3-460C-B924-E43BA7E18165Q42210504-B551BFC6-6FB4-40B1-9110-4A4E056C4FCEQ42908869-5E117F67-BCE7-4D16-8EA2-35FBA5FF35BAQ43226964-7AD1014E-F8CE-4408-9363-5D98CE3AF7ABQ46532816-A5153BDA-7D64-4C3C-9017-EF3A059668F6Q47939381-9576FB01-7347-4645-BF65-6EC0F818CDD1Q49598865-52C582BF-3350-40E5-8C18-BC2954BD51EFQ52695014-74711FD5-344A-47DB-8D5A-DB69B8837223Q53681200-BB20BBA4-462F-4968-9D8F-7124E65DCDD8
P2860
Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Efficacy and safety of aminogl ...... randomized controlled trials.
@ast
Efficacy and safety of aminogl ...... randomized controlled trials.
@en
type
label
Efficacy and safety of aminogl ...... randomized controlled trials.
@ast
Efficacy and safety of aminogl ...... randomized controlled trials.
@en
prefLabel
Efficacy and safety of aminogl ...... randomized controlled trials.
@ast
Efficacy and safety of aminogl ...... randomized controlled trials.
@en
P2093
P50
P356
P1476
Efficacy and safety of aminogl ...... randomized controlled trials.
@en
P2093
Anat Gafter-Gvili
Liat Vidal
Sara Borok
P304
P356
10.1093/JAC/DKM193
P407
P577
2007-06-11T00:00:00Z